Figure 1

Sample size and segmentation into strata of different antidiabetic-treatments. Legend: Patients are eligible for inclusion if treated with oral mono or dual combination therapy and are distributed into the following groups: Incretin-based treatments include DPP-4 inhibitors and GLP-1 analogues. Non-incretin-based therapies include metformin, sulfonylureas, acarbose, insulin, alpha-glucosidase inhibitors, and SGLT2-inhibitors.